National Association of Counties

Blog

FDA approves Pfizer and Moderna booster doses, authorizes mix and match for COVID-19 vaccines

By Blaire Bryant, Carlos Aguilera   Oct. 25, 2021
Tags: Health

Error message

In order to filter by the "in queue" property, you need to add the Entityqueue: Queue relationship.
  • Blog

    FDA approves Pfizer and Moderna booster doses, authorizes mix and match for COVID-19 vaccines

    On October 21, the Centers for Disease Control and Prevention (CDC) endorsed the use of Moderna and Johnson & Johnson booster shots following a recommendation from the Advisory Committee on Immunization Practices’ (ACIP). The endorsement follows the Food and Drug Administration’s (FDA) October 20 announcement approving the emergency use of booster doses for both vaccines.

    The CDC also endorsed the use of heterologous (mix and match) COVID-19 vaccine booster shots, following FDA approval based on safety and efficacy data. Eligible individuals will be able to select their booster dose from any of the FDA endorsed or approved COVID-19 vaccines.

    Updated guidelines for the use of a COVID-19 vaccine booster dose are as follows:

    • Johnson & Johnson COVID-19 vaccine: A single booster dose may be administered at least two months after completion of the single-dose primary regimen to individuals 18 years of age and older.
    • Moderna COVID-19 vaccine: A single booster dose may be administered at least six months after completion of the primary series to individuals that are 65 years of age and older, 18 through 64 years of age at high risk of severe COVID-19, or 18 through 64 years of age with frequent institutional or occupational exposure to COVID-19.
    • Pfizer-BioNTech COVID-19 vaccine: A single booster dose may be administered at least six months after completion of the primary series to individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.

    As key providers of local public health services and frontline service providers for the medically vulnerable, counties have supported over 190 million vaccinations in the U.S. to date and will continue to play an essential role in the administration of COVID-19 vaccines and boosters. For more information on how county health facilities can prepare for the distribution of COVID-19 boosters, see the “Vaccine Booster Readiness Checklist for County Health Facilities” tab in NACo’s COVID-19 Vaccine Distribution Toolkit.

    ADDITIONAL RESOURCES

    • NACo’s COVID-19 Vaccine Distribution Toolkit
    • NACo Brief: The County Role in Vaccines
    • NACo Blog: FDA panel recommends COVID-19 booster shots for older adults and high-risk individuals

    On October 21, the Centers for Disease Control and Prevention (CDC) endorsed the use of Moderna and Johnson & Johnson booster shots following a recommendation from the Advisory Committee on Immunization Practices’ (ACIP).
    2021-10-25
    Blog
    2021-11-04

FDA approves Moderna and J&J COVID-19 boosters and the “mix and match” use of vaccines CDC endorses advisory committee’s recommendation for booster doses of Moderna and J&J As key providers of local public health services, counties will play an essential role in the administration of COVID-19 boosters

On October 21, the Centers for Disease Control and Prevention (CDC) endorsed the use of Moderna and Johnson & Johnson booster shots following a recommendation from the Advisory Committee on Immunization Practices’ (ACIP). The endorsement follows the Food and Drug Administration’s (FDA) October 20 announcement approving the emergency use of booster doses for both vaccines.

The CDC also endorsed the use of heterologous (mix and match) COVID-19 vaccine booster shots, following FDA approval based on safety and efficacy data. Eligible individuals will be able to select their booster dose from any of the FDA endorsed or approved COVID-19 vaccines.

Updated guidelines for the use of a COVID-19 vaccine booster dose are as follows:

  • Johnson & Johnson COVID-19 vaccine: A single booster dose may be administered at least two months after completion of the single-dose primary regimen to individuals 18 years of age and older.
  • Moderna COVID-19 vaccine: A single booster dose may be administered at least six months after completion of the primary series to individuals that are 65 years of age and older, 18 through 64 years of age at high risk of severe COVID-19, or 18 through 64 years of age with frequent institutional or occupational exposure to COVID-19.
  • Pfizer-BioNTech COVID-19 vaccine: A single booster dose may be administered at least six months after completion of the primary series to individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.

As key providers of local public health services and frontline service providers for the medically vulnerable, counties have supported over 190 million vaccinations in the U.S. to date and will continue to play an essential role in the administration of COVID-19 vaccines and boosters. For more information on how county health facilities can prepare for the distribution of COVID-19 boosters, see the “Vaccine Booster Readiness Checklist for County Health Facilities” tab in NACo’s COVID-19 Vaccine Distribution Toolkit.

ADDITIONAL RESOURCES

Related Posts

Related Resources

Related Resources

Related Events

More From